Promotions & Moves

BeiGene Names Interim Chief Medical Officer

Current CMO RuiRong Yuan to leave company

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BeiGene, a clinical-stage biopharma focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has appointed Eric Hedrick as its interim chief medical officer. Current chief medical officer, RuiRong Yuan, will leave the company. Mr. Hedrick has served as a clinical advisor to BeiGene since June 2015. He was previously chief medical officer at Epizyme, and vice president of oncology development and interim chief medical officer at Pharmacyclics, where he ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters